Accent Therapeutics
PrivateLast Round
Series C
Jan 23, 2024
Total Funding Raised
$178M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Accent Therapeutics operates in Healthcare & Life Sciences and is based in Lexington, Massachusetts. Its latest recorded funding round was a Series C round in January 2024.
Accent Therapeutics is a biopharmaceutical company that develops small molecule precision oncology therapies targeting RNA-modifying proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accent Therapeutics Comparables
Compare Accent Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EPICS Therapeutics | 86% | |
| STORM Therapeutics | 85% | |
| Remix Therapeutics | 84% |
For institutional investors. Book with your work email.
Accent Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 23, 2024 | ||||
| Series B | Apr 23, 2020 | ||||
| Series A | Sep 18, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Accent Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C, Series A, Series B |
| The Column Group | Series A, Series B, Series C |
| GV | Series B, Series C |
| Mirae Asset | Series C |
| Droia Ventures | Series B, Series C |
| The Chernin Group | Series B, Series C, Series A |
| AbbVie Ventures | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 48% MoM.
- Apr 17, 2026
New data for KIF18A inhibitor ATX-295 presented at AACR Annual Meeting.
For institutional investors. Book with your work email.
Accent Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Accent Therapeutics's valuation, stock price, and market status.
Is Accent Therapeutics a public or private company?
Accent Therapeutics is a private company.
What is the current stock price of Accent Therapeutics?
Accent Therapeutics is a private company, so its shares have no public market price. Caplight tracks Accent Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Accent Therapeutics worth (valuation)?
Valuation information for Accent Therapeutics is not publicly available.
Can I buy Accent Therapeutics stock?
Accent Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Accent Therapeutics's last funding round?
Accent Therapeutics's most recent funding round was Series C on January 23, 2024.
Who are the main investors in Accent Therapeutics?
Key investors in Accent Therapeutics include EcoR1 Capital, Mirae Asset, The Chernin Group, Mirae Asset Capital Life Science, Atlas Venture.
Will Accent Therapeutics IPO soon?
No public IPO plans have been announced for Accent Therapeutics.
How can I track Accent Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Accent Therapeutics's shares on secondary markets.